^
Association details:
| Biomarker: | HLA-A*02:01 + CTAG1B expression |
|---|---|
| Cancer: | Soft Tissue Sarcoma |
| Drug: | TAEST16001 (TCR modulator, NY ESO 1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase 1 clinical trial to assess safety and efficacy of NY-ESO-1-specific TCR T cells in HLA-A∗02:01 patients with advanced soft tissue sarcoma
Published date:
08/15/2023
Excerpt:
...data from this phase 1 clinical trial showed that autologous T cells engineered to express a high-affinity NY-ESO-1-specific TCR derived from PBMCs of an HLA-matched healthy donor are safe and highly active in the HLA-A∗02:01 population with advanced STS expressing NY-ESO-1 antigens.
DOI:
https://doi.org/10.1016/j.xcrm.2023.101133
Trial ID:
